---
title: "Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302448893.md"
description: "Arcus Biosciences shares rose after ARC-20 platform data showed its kidney cancer drug casdatifan outperformed competitors, with a 35-month median overall survival in late-line patients. Analysts from TD Cowen and Leerink praised the results, highlighting casdatifan's potential as a foundational RCC therapy and predicting significant stock gains."
datetime: "2026-10-20T16:35:19.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302448893.md)
  - [en](https://longbridge.com/en/news/302448893.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302448893.md)
generator: "portal-rs"
---

# Arcus rises as analysts cheer ARC-20 platform data for kidney cancer drug


### Related Stocks

- [RCUS.US](https://longbridge.com/en/quote/RCUS.US.md)

## Related News & Research

- [RCUS: Casdatifan data support its potential as a backbone across kidney cancer treatment lines](https://longbridge.com/en/news/302426624.md)
- [Arcus Biosciences Closes $269.7 Million Stock Offering](https://longbridge.com/en/news/302923681.md)
- [Arcus Biosciences Announces New Employment Inducement Grants | RCUS Stock News](https://longbridge.com/en/news/303130364.md)
- [Arcus reports 35-month median overall survival for casdatifan in late-line kidney cancer study](https://longbridge.com/en/news/302422176.md)
- [Arcus Biosciences Announces Pricing of $250 Million Public Offering of Common Stock | RCUS Stock News](https://longbridge.com/en/news/302638824.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**